Latest stories on ARVN
Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation
GlobeNewswire56 · neutralproduct/pr
Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026
Business Insider50 · neutralgeneral
Arvinas presents data from clinical trial of ARV-102
The Fly59 · neutralproduct/pr
Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease
GlobeNewswire63 · neutralproduct/pr
Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease
Business Insider63 · neutralproduct/pr
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire50 · neutralgeneral
Arvinas announces first patient dosed in Phase 1/2 trial of ARV-6723
The Fly59 · neutralproduct/pr
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate
GlobeNewswire63 · neutralproduct/pr
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate
Business Insider63 · neutralproduct/pr
Arvinas, Inc. (ARVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha56 · neutralgeneral
Arvinas (ARVN) Just Made Protein Degrader History With FDA Nod
Yahoo Finance78 · bullishproduct/pr
Arvinas to Participate in Upcoming Investor Conferences
GlobeNewswire56 · neutralgeneral
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire50 · neutralgeneral
Arvinas: Veppanu Approval Underlines Degrader Platform Promise - I'm Bullish
Seeking Alpha68 · bullishanalyst
Arvinas (ARVN) Q2 2026 Earnings Call Transcript
The Motley Fool73 · bullishearnings
Arvinas Price Target Lowered To 10 From 11 At Morgan Stanley
The Fly34 · bearishanalyst
Arvinas price target lowered to $14 from $19 at Evercore ISI
The Fly34 · bearishanalyst
Arvinas Price Target Lowered To 21 From 24 At Citi
The Fly34 · bearishanalyst
Arvinas Launches New Cancer Combo Trial, Adding Fresh Optionality to ARVN
TipRanks63 · neutralproduct/pr
BTIG reiterates Arvinas stock Buy rating on pipeline execution
Investing.com Analyst Ratings63 · neutralanalyst
Arvinas expects cash runway into the second half of 2028 as ARV-102 PSP trials shift to 2027
Seeking Alpha56 · neutralgeneral
Arvinas, Inc. (ARVN) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
ARVN Sees Landmark PROTAC Approval and Revenue Surge as Pipeline Advances Toward Major Clinical Milestones
August 4, 2026
MarketChameleon78 · bullishproduct/pr
Why is Arvinas stock surging today?
Investing.com Markets50 · neutralgeneral